Crossmark

Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer

Crossref DOI link: https://doi.org/10.1007/s10067-024-07135-8

Published Online: 2024-09-04

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suarez-Almazor, Maria E. https://orcid.org/0000-0001-5381-5797
Ruiz, Juan I.

Lei, Xiudong

Wu, Chi-Fang

Zhao, Hui

Rajan, Suja S.

Giordano, Sharon H.
Funding

Funding for this research was provided by:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR078484)

The University of Texas MD Anderson's Cancer Center Support Grant from NIH/NCI (P30 CA016672)

Susan G. Komen (SAC-150061)

Cancer Prevention and Research Institute of Texas (RP160674)
License Information

Text and Data Mining valid from 2024-09-04

Version of Record valid from 2024-09-04
More Information

Article History

Received: 3 June 2024

Revised: 29 August 2024

Accepted: 31 August 2024

First Online: 4 September 2024

Declarations

:

: None.

Document is current

Any future updates will be listed below